Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1981 2
1982 3
1983 3
1984 6
1985 2
1986 3
1987 5
1988 3
1989 8
1990 12
1991 7
1992 10
1993 6
1994 14
1995 14
1996 10
1997 13
1998 17
1999 24
2000 24
2001 43
2002 48
2003 54
2004 64
2005 86
2006 98
2007 119
2008 127
2009 148
2010 149
2011 138
2012 186
2013 199
2014 299
2015 328
2016 321
2017 378
2018 382
2019 415
2020 522
2021 607
2022 532
Text availability
Article attribute
Article type
Publication date

Search Results

4,915 results
Results by year
Filters applied: . Clear all
Page 1
Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence.
Belk JA, Yao W, Ly N, Freitas KA, Chen YT, Shi Q, Valencia AM, Shifrut E, Kale N, Yost KE, Duffy CV, Daniel B, Hwee MA, Miao Z, Ashworth A, Mackall CL, Marson A, Carnevale J, Vardhana SA, Satpathy AT. Belk JA, et al. Among authors: yao w. Cancer Cell. 2022 Jul 11;40(7):768-786.e7. doi: 10.1016/j.ccell.2022.06.001. Epub 2022 Jun 23. Cancer Cell. 2022. PMID: 35750052
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.
Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, Yao W, Wang R, Li X, Zhang W, Zhang Y, Hu S, Guo R, Shi J, Wang Z, Cao P, Wang D, Fang J, Luo H, Geng Y, Xing C, Lv D, Zhang Y, Yu J, Cang S, Yang Z, Shi W, Zou J, Zhou C; CameL-sq Study Group. Ren S, et al. Among authors: yao w. J Thorac Oncol. 2022 Apr;17(4):544-557. doi: 10.1016/j.jtho.2021.11.018. Epub 2021 Dec 16. J Thorac Oncol. 2022. PMID: 34923163 Clinical Trial.
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Wang J, Li P, Qin M, Lu D, Yang J. Zhou C, et al. Among authors: yao w. Lancet Oncol. 2022 Feb;23(2):220-233. doi: 10.1016/S1470-2045(21)00650-1. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038432 Clinical Trial.
Long-Term Ozone Exposure and Small Airway Dysfunction: The China Pulmonary Health (CPH) Study.
Niu Y, Yang T, Gu X, Chen R, Meng X, Xu J, Yang L, Zhao J, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Huang K, Chen Y, Sun T, Shan G, Lin Y, Wu S, Zhu J, Wang R, Shi Z, Xu Y, Ye X, Song Y, Wang Q, Zhou Y, Ding L, Yang T, Yao W, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Liang L, Cao B, Dai H, Wu T, He J, Li H, Kan H, Wang C; China Pulmonary Health Study Group. Niu Y, et al. Among authors: yao w. Am J Respir Crit Care Med. 2022 Feb 15;205(4):450-458. doi: 10.1164/rccm.202107-1599OC. Am J Respir Crit Care Med. 2022. PMID: 34813411
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.
Koblish HK, Wu L, Wang LS, Liu PCC, Wynn R, Rios-Doria J, Spitz S, Liu H, Volgina A, Zolotarjova N, Kapilashrami K, Behshad E, Covington M, Yang YO, Li J, Diamond S, Soloviev M, O'Hayer K, Rubin S, Kanellopoulou C, Yang G, Rupar M, DiMatteo D, Lin L, Stevens C, Zhang Y, Thekkat P, Geschwindt R, Marando C, Yeleswaram S, Jackson J, Scherle P, Huber R, Yao W, Hollis G. Koblish HK, et al. Among authors: yao w. Cancer Discov. 2022 Jun 2;12(6):1482-1499. doi: 10.1158/2159-8290.CD-21-1156. Cancer Discov. 2022. PMID: 35254416 Clinical Trial.
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: yao w. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
Jiang T, Chen J, Xu X, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, Yao W, Wang R, Li X, Zhang W, Zhang Y, Hu S, Guo R, Shi J, Wang Z, Cao P, Wang D, Fang J, Luo H, Geng Y, Xing C, Lv D, Zhang Y, Yu J, Cang S, Zhang Y, Zhang J, Yang Z, Shi W, Zou J, Zhou C, Ren S. Jiang T, et al. Among authors: yao w. Mol Cancer. 2022 Jan 3;21(1):4. doi: 10.1186/s12943-021-01479-4. Mol Cancer. 2022. PMID: 34980131 Free PMC article. Clinical Trial.
4,915 results